Ex vivo anticoagulants affect human blood platelet biomechanics with implications for high-throughput functional mechanophenotyping

Commun Biol. 2022 Jan 21;5(1):86. doi: 10.1038/s42003-021-02982-6.

Abstract

Inherited platelet disorders affecting the human platelet cytoskeleton result in increased bleeding risk. However, deciphering their impact on cytoskeleton-dependent intrinsic biomechanics of platelets remains challenging and represents an unmet need from a diagnostic and prognostic perspective. It is currently unclear whether ex vivo anticoagulants used during collection of peripheral blood impact the mechanophenotype of cellular components of blood. Using unbiased, high-throughput functional mechanophenotyping of single human platelets by real-time deformability cytometry, we found that ex vivo anticoagulants are a critical pre-analytical variable that differentially influences platelet deformation, their size, and functional response to agonists by altering the cytoskeleton. We applied our findings to characterize the functional mechanophenotype of platelets from a patient with Myosin Heavy Chain 9 (MYH9) related macrothrombocytopenia. Our data suggest that platelets from MYH9 p.E1841K mutation in humans affecting platelet non-muscle myosin heavy chain IIa (NMMHC-IIA) are biomechanically less deformable in comparison to platelets from healthy individuals.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anticoagulants / pharmacology*
  • Biomechanical Phenomena
  • Blood Platelets / classification*
  • Blood Platelets / drug effects*
  • Gene Expression Regulation / drug effects
  • High-Throughput Screening Assays
  • Humans
  • Mutation
  • Myosin Heavy Chains / genetics*
  • Platelet-Rich Plasma
  • Specimen Handling

Substances

  • Anticoagulants
  • MYH9 protein, human
  • Myosin Heavy Chains